Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit

SEATTLE, August 23, 2023 – Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary best in class data from an ongoing non-human primate study for the first time at the 8th CAR-TCR Summit being held August 29-September 1 in Boston, MA.

Presentation Details:

Presentation Title: Surface Engineering of VivoVec Generates Potent In Vivo CAR-T Achieving Durable B Cell Aplasia in Non-Human Primate Model
Presenting Speaker: Byoung Ryu, Ph.D., Executive Vice President of Discovery Research & Vector Biology
Presentation Date/Time: Friday, September 1, 2023, at 11:00 AM ET
Track: Discovery
Session Title: Leveraging Next Generation Gene Delivery & Transduction

Key Topics to be Discussed:

  • Development of VivoVec particles for in vivo CAR-T cell generation
  • VivoVec surface engineering enables preferential binding, activation, and transduction of T cells in vivo
  • A single infusion of VivoVec particles generated mid double-digit percentages of circulating CAR T-cells and achieved durable B cell aplasia in the initial three non-human primate experimental animals treated with a full human target dose

About Umoja Biopharma
Umoja Biopharma, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy. The Company is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies. Founded based on pioneering work performed at Seattle Children’s Research Institute and Purdue University, Umoja’s novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec™ off-the-shelf in vivo delivery platform and the RACR™/CAR in vivo cell expansion/control platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Umoja Biopharma, Inc. (the “Company,” “we,” “us,” or “our”). The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as any economic, market and social disruptions. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. 

Umoja Media Contact:
Karissa Cross, Ph.D.
LifeSci Communications